Friday August 5th, 2016 09:03 Dendreon’s Scientific Breakthrough Fails To Sell

[wikinvestchart ticker=”DNDN” range=”recent” rolling=”1 day” height=”245″ width=”390″ live_quote=”true” annotations=”false”]Dendreon shares are down 60% after the company announced second quarter sales that fell well below investor expectations and withdrew its financial guidance for its only product, the prostate cancer treatment Provenge. Maybe the Seattle biotech company should respond by …

Related Blogs

    Comment Form

    Your name

    Your email

    Your URL